License and Collaboration Agreements (Tables)

3 Months Ended

Mar. 31, 2014

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Revenue Recognized and Assets and Liabilities under Collaborative Arrangements

During the three months ended March 31, 2014 and 2013, the Company recognized revenue based on the following components of the Sanofi agreement:

	Three months ended March 31,
(in thousands)	2014		2013
Upfront payment	$	1,250	$	1,250
Milestone payment		521		521
Development services		10,700		11,590
Manufacturing services and other		563		741
Total	$	13,034	$	14,102

The Company performs development services for which revenue is recognized under the Sanofi agreement in accordance with the specified budget period. Additionally, for the period ended March 31, 2014, there is approximately $5.8 million of increased revenue related to the Company receiving budget approval for expenses incurred during the year ended December 31, 2013.

As of March 31, 2014 and December 31, 2013, the Company maintained the following assets and liabilities related to the Sanofi agreement:

(in thousands)	March 31, 2014		December 31, 2013
Accounts receivable, billed	$	4,283	$	2,357
Accounts receivable, unbilled		7,513		3,417
Deferred revenues		71,058		73,392